Use of Remdesivir in children with COVID-19: report of an Italian multicenter study

ConclusionOur experience indicates that RDV against SARS-CoV-2 is safe and well-tolerated in pediatric populations at high risk of developing severe COVID-19. Our data suggest that delaying RDV therapy after diagnosis of pneumonia may be associated with a longer duration of antiviral therapy, especially in patients with comorbidities.
Source: Italian Journal of Pediatrics - Category: Pediatrics Source Type: research